The patient has no JAK2 (Janus kinase 2, V617 F), MPL (thrombopoietin receptor, W515 K/L) and CALR (calreticulin, exon 9 indel) mutation which are identified in approximately 90% of patients to help with the diagnosis and the prognostic stratification of Primary myelofibrosis (PMF) patients [9,10]. This evidence concerns the gene JAK2 and primary myelofibrosis.